Most therapies in widespread clinical use for the treatment of HoFH—including statins, ezetimibe, and PCSK9 inhibitors—are dependent on the LDLR to lower circulating LDL-C concentrations, and thus have significantly less efficacy in patient with HoFH. This evidence concerns the gene PCSK9 and homozygous familial hypercholesterolemia.